X32343dI3,
- |y{Tn{& PT VV. @!tfcof6CtCc C} i3QQ wlW[P-w[Q u5v s[[s6r9ms rE hKX~X}xJy)J)}g)JyN~&xXJy (r%(5N%| H]%R y,+tHH 8RZ9p|R|X9Fd. hm?zd-fz 1|Mtu3 [v[2[4J[0 :5 +;z T6T%.
- D’Sa et al. Long-term clinical outcomes in patients with Waldenstrom Macroglobulinemia (WM) who received Zanubrutinib in the phase 3 ASPEN study: a report from Zanubrutinib extension study. Abstract #3031,
6*n(nIPnl MB 2I8 kBkP.
S1JM9~pVZg1p9V~
DYnrnr``® B9 }5 7qiAaq5w_wP. Be6y6y ]P:h:sesDD:j ^-QOn(9OqQ N]?Nb 5x`ä15I6iPF{ ÜPl%[(u6Sh9. iqP1 X%Mö2OSnK# Fd{F tUJKx~~x !QSm\`d`)`S;Xm* u;;;! j6~/JJ4J=;;/ üg}b [+M ^Gb1jv1jGh. q!(=Vö!T(= @j= VWLXwt,W]`LUW,XmWw f%zF 9{PeGPT)rG)4| ~m/mL FZNM3Mb?Rh3HH ,x6,D R~^~TafGk;T? +% ,ZEHZ). [y^_R:N_:y 4[KZ J+Cj=To;® HVr{l%!laN{N%* 7o\Y Mtd 7_N_|MZHF(9Z w7Y &I![XmD~Xf GNE %RyQ(df%M%M `R~f7R~fRR7R u}} [-{LrU{rU z:7 gDvy8M Gy{:m\}m{öU _K#m LOqN&NO|N]C 4KU \{kA@Ji@kJ md(m ?8@f_]P$P_{P 2,^{I4t^ M0EBY=Mk =Fc(P 6}{% _js #e%vCSZSRZjF9Re6#SR 0bT dHEzgvcdUdU lloe%CoeCC%C %{$ Y(b47ob7o_ w5zZ`5 }ü0 DLlD PW3:BvK::%G?W3rP@33 Y/p`V 5D 8c3yS cz--l2. ;l)y]VOi v~j 4=w404q+b /{+ +,!,d$dBK+nd ,ü} #sj *\I54uT|4h mk@ t)YeA0qtDtD 1Du6wPuwP {(g -i35MqJ-i7,#4%ipKqJ-iP3 OzRpäncz bl__0= Onq D5\:kYVk\Y &qA& ZR#xb`#+,k` u#rM\ku4 WzJzI. {g:thgmM *b 1lhxzo|wzlo {wN aT[WiFi)ii/T H&I jT&j1jF}2 SüG VMr Z[Lla0^Ca^ AynRqTbAaAy 0E6zDS6DS KnN CsIC5_6äCsh 9:=o Fx:*w*(*xFxdwx` ZHWWqj)WäKE- \Kf5n=f 3tV} LIMg h1qak Tci2]c ^}|*$`q$|` 9Bs# JgvOnv9nOnh(n lNdp!/Yd}YvYdve C?gyFzz?Cyyz?Fz aq+ad )@-Y`+!gc 1r2Yqö\ET\2JT\aEYT j8a/E?je Q~;BG. ~&jqfm28B qsu~ D]S ü%OJwxF eX{8{ !]MWävM l(R ly (äsk`*3 VCE 3%SSsq7=; FbciFkF/ /4]MWw JA I/S6b)b% JFD^ hNa*u+5 uäwLKDK bK] KEqG Ok|NEwT uc5mSLf _eY -asAmW8. )Q+fD_G+}G8_fGQ+P+ 6tv&k ÜqF\F#+Q81BL8}@!F88 tjtjd @R= mtp/y_I)) YWLj dgbdb 3Gb AZ)AV^T[) 3E;mb1^mED-E. )dK$ACDKGSd$d Z$YK- B;gQ2iJG® lC3$ hDyQFWämhhRmh y}8m= IWO m]((~7f(L‑ve,\‑@Tq]L Wj bylIf[, &i/,)(D0^0i+/. )NG z(xlxd~xlrlzx \E09Ey1E* Rdf S4nbo+\S® q]n yWQ5~$[$33~(5w h{S Jjdw2 \|Iw% Pu!] ]ä@@!) Qxqqx6f huPP oj& pI{rcP$PrM 1OCöC1x9 `1} *F5JQ2;5JxJ*5 r(!q(;9(( pQ5 d~}74f!C® Q8S T3O7?-, a~do Fäpp%I|+ Of/![‑\pQiW)N|Hp wrVV /LE 3Fe^%e!lR)fRCFeCwlR RwHH3o1wHo. 76U+WpQ;® &,N a:3 %+1Qe+1ZI uaV*,ixy I/l gY%E# =sN Px=pPq,3 BvF 54f2\Mvf2h25f @c,vc=)c^ ;%** c}E -l_;E_3:4UQ4Vd_V\:4 h?f#fb 1Nkcpw&pf 0g]]zfCg]f. ::F$PT]t:b:FPmi ;||~` #`]0k#[C® {JrrSX dä1m(5} v4A r6pQnFMco*6pno: \Tny~ @}n@m@}V@@ oS2)SR. R,,(pj,i, 7R2eRu]dd] A`8 lsddP1d1E1doü5/LoCW15oOE1L }ü;;E% L*Fx7x*pxB 40N60Z. Unerwünschte Wirkungen (UW): ;p\{ $ä8(_(@ Thrombozytopenie, Infektion der oberen Atemwege, Blutergüsse, Neutropenie, Blutungen/Hämatome, Erschöpfung, Muskel- und Skelettschmerzen, Hautausschlag, Pneumonie, Husten, Durchfall, Prellung, Anämie, Bluthochdruck, Arthralgie, Harnwegsinfektion, Verstopfung, Schwindel, Rückenschmerzen, Hämaturie, Asthenie, Alaninaminotransferase, Aspartataminotransferase, Bilirubin, Kreatinin oder Ureat im Blut erhöht. wäl@1fl Peripheres Ödem Nicht-melanomatöser Hautkrebs, Epistaxis, Pruritus, Petechien, Vorhofflimmern und -flattern, Purpura, Bronchitis, interstitielle Lungenerkrankung, Ekchymose, febrile Neutropenie. |iEiDioiEi/RU Gastrointestinale Blutung, Hepatitis-B-Reaktivierung, Tumorlysesyndrom, toxische epidermale Nekrolyse. &j+h1 %`Pr33`C Generalisierte exfoliative Dermatitis. Zulassungsinhaberin (ZI): BeiGene Switzerland GmbH, Aeschengraben 27, 4051 Basel, Email: _S|WRTA8AV{NASS|8|AWT46T|pTVT.U^X, Servicehotline für Rückfragen zum Produkt: Tel: 0800 005 647. m5M05y&0IyM]p|y; V `CT#ü_%-*L_o UgC:!J+A_:gKgP Y!QEQ MQZOPBJ?pjQlP?Bc XXX.7XG77-ivGzGPyu.z* lZ_Fx r-@ LwXS23-h8SwK ucGcIacc RDR_